BidaskClub lowered shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a strong sell rating in a report issued on Saturday.

Several other analysts have also recently weighed in on PRTK. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a hold rating to a buy rating and set a $21.00 price target on the stock in a report on Saturday, August 5th. Cantor Fitzgerald reiterated an overweight rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 8th. Raymond James Financial reiterated a strong-buy rating and issued a $36.00 price target on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. ValuEngine cut shares of Paratek Pharmaceuticals from a hold rating to a sell rating in a report on Monday, September 18th. Finally, Guggenheim initiated coverage on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. They issued a buy rating and a $44.00 price target on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $40.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) traded down $0.20 during trading hours on Friday, reaching $18.65. 554,971 shares of the company traded hands, compared to its average volume of 338,396. Paratek Pharmaceuticals has a twelve month low of $12.90 and a twelve month high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49.

Several hedge funds have recently made changes to their positions in PRTK. TIAA CREF Investment Management LLC boosted its holdings in shares of Paratek Pharmaceuticals by 11.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 75,076 shares of the specialty pharmaceutical company’s stock valued at $1,445,000 after buying an additional 7,844 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Paratek Pharmaceuticals by 9.5% during the 1st quarter. Vanguard Group Inc. now owns 724,300 shares of the specialty pharmaceutical company’s stock valued at $13,942,000 after buying an additional 63,121 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Paratek Pharmaceuticals by 10.7% during the 1st quarter. Geode Capital Management LLC now owns 148,962 shares of the specialty pharmaceutical company’s stock valued at $2,867,000 after buying an additional 14,392 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Paratek Pharmaceuticals by 160.2% during the 1st quarter. Morgan Stanley now owns 154,693 shares of the specialty pharmaceutical company’s stock valued at $2,978,000 after buying an additional 95,243 shares in the last quarter. Finally, Credit Suisse AG boosted its holdings in shares of Paratek Pharmaceuticals by 36.6% during the 1st quarter. Credit Suisse AG now owns 18,110 shares of the specialty pharmaceutical company’s stock valued at $349,000 after buying an additional 4,853 shares in the last quarter. Hedge funds and other institutional investors own 84.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Paratek Pharmaceuticals (PRTK) Downgraded by BidaskClub to Strong Sell” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/03/paratek-pharmaceuticals-prtk-downgraded-by-bidaskclub-to-strong-sell.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.